GET DAILY SIGNALSSI-BONE (SIBN) Delivers +14.5% Revenue Growth in Q3 2026
Key Takeaways
- Worldwide revenue reached $55.7 million in the third quarter of 2026, up 14.5% year over year from $48.7 million.
- Net loss narrowed to $3.6 million, or $0.08 per diluted share, beating the consensus estimate of a $0.13 per share loss.
- Adjusted EBITDA improved to $3.0 million from $2.3 million a year earlier.
- SI-BONE reaffirmed its full-year 2026 revenue guidance of $231 million to $233 million while lowering its operating expense growth outlook to 10.5%.
- Active U.S. physicians grew 16% year over year to roughly 1,770, and the alpha launch of iFuse Granite Onyx began expanding the company's addressable market.
Earnings Context and Why It Matters
SI-BONE, a developer of procedural solutions for compromised bone, delivered its third-quarter 2026 results as the company pushes into new clinical adjacencies beyond its core sacroiliac joint franchise. I am watching whether the recent FDA clearance of iFuse Granite Onyx and favorable reimbursement changes can accelerate procedure volumes and broaden the company's total addressable market. The quarter also tests SI-BONE's path toward sustainable profitability, as improving operating leverage and disciplined expense management remain central to the investment thesis in a competitive medtech landscape.
Reported Results
SI-BONE reported worldwide revenue of $55.7 million for the third quarter of 2026, a 14.5% increase from $48.7 million in the prior-year period and slightly above the consensus estimate of about $55.3 million. U.S. revenue grew 13.9% to $52.8 million, driven by a 19.5% rise in procedure volume, partially offset by lower average selling price tied to procedure mix and growing adoption of the INTRA platform in office-based and ambulatory surgery center settings. International revenue rose 27.0% to $2.9 million.
The company's net loss improved 20.7% to $3.6 million, or $0.08 per diluted share, compared with a net loss of $4.6 million, or $0.11 per share, a year earlier. Gross margin was 79.3%, slightly below the prior-year 79.8%, reflecting procedure and site-of-care mix. Operating expenses increased 9.7% to $48.5 million, while adjusted EBITDA climbed to $3.0 million from $2.3 million. Cash and equivalents stood at $146.3 million at quarter end. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Shares of SI-BONE have been supported by improving fundamentals heading into the report, with the stock up roughly 11% over the prior three months and about 35% over the prior twelve months. The third-quarter beat on both revenue and earnings per share, combined with reaffirmed full-year guidance, reinforced the view that the company's procedure-driven growth remains intact. The market also appeared focused on the early traction of the iFuse Granite Onyx alpha launch, which management framed as a meaningful expansion of its addressable market, and on the October 1, 2026 diagnosis-related group reimbursement changes that could lift procedure economics.
Forward Outlook and Key Factors to Monitor
SI-BONE reaffirmed its full-year 2026 revenue guidance of $231 million to $233 million, implying roughly 15% to 16% growth, and maintained its gross margin expectation of approximately 79.0%. Management also reduced its operating expense growth outlook to 10.5% from 12.0%, reflecting disciplined spending and operating leverage.
Looking ahead, investors should monitor the commercial ramp of iFuse Granite Onyx, which management says expands the estimated total addressable market to roughly $5 billion. The company has also filed for a New Technology Add-on Payment, which, if approved by CMS, would take effect in October 2027.
Other factors to watch include the pace of physician adoption across the INTRA and TORQ platforms, the impact of proposed reimbursement increases for hospital outpatient and ASC settings, and the company's progress toward its target of nearly 100 sales territories exiting 2026. Cost discipline, gross margin stability, and continued positive adjusted EBITDA will remain key markers of SI-BONE's path toward profitability.
Integrating AI Tools Into My Analysis
I frequently use Tickeron’s AI Screener to quickly filter opportunities and compare fundamentals across the medtech space. It helps surface relevant data points on growth trends and valuation metrics that support deeper review of names like this one, keeping the process efficient without replacing traditional due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SIBN saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for SIBN moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 61 similar instances where the indicator exited the overbought zone. In 46 of the 61 cases the stock moved lower. This puts the odds of a downward move at 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SIBN moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 19 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SIBN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
SIBN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SIBN as a result. In 62 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for SIBN just turned positive on October 05, 2026. Looking at past instances where SIBN's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
SIBN moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SIBN crossed bullishly above the 50-day moving average on October 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +4.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where SIBN advanced for three days, in 211 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 138 of 194 cases where SIBN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.970) is normal, around the industry mean (4.204). P/E Ratio (-61.273) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.801) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. SIBN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SIBN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a sacroiliac joint medical device company
Industry MedicalNursingServices
Advertisement